4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

ACSM Certified Clinical Exercise Physiologist ACSM-CEP

Track your progress as you read

Finished sections get a check mark.

1 Introduction & Exam Overview

1.1 The ACSM-CEP Role, Job Definition & Scope of Practice 1.2 Exam Format, Domain Weights & Scoring 1.3 Eligibility, Study Planning & Test-Day Strategy

2 Applied Exercise Physiology & Metabolic Calculations

Bioenergetics & Energy Systems (ATP-PC, glycolytic, oxidative) Acute Cardiorespiratory & Metabolic Responses to Aerobic Exercise Responses to Resistance Exercise & Chronic Training Adaptations ACSM Metabolic Equations, METs & Interpreting VO₂ / RER / Ventilatory Threshold

3 Pathophysiology of Clinical Populations

3.1 Coronary Artery Disease, Myocardial Infarction & Revascularization (PCI/CABG) 3.2 Heart Failure, Valvular Disease & Cardiac Rhythm Disorders 3.3 Hypertension, Dyslipidemia & Peripheral Artery Disease 3.4 Pulmonary Disease: COPD, Asthma & Restrictive/Interstitial Disorders 3.5 Diabetes, Metabolic Syndrome & Obesity 3.6 Renal Disease & Musculoskeletal/Orthopedic Conditions 3.7 Neuromuscular, Neurological & Cognitive Conditions (stroke, MS, Parkinson's, SCI) 3.8 Neoplastic, Immunologic & Hematologic Disorders (cancer, HIV/AIDS, anemia)

4 Clinical ECG Interpretation

4.1 ECG Leads, Waveforms, Rate & Rhythm Determination 4.2 Arrhythmias & Conduction Blocks 4.3 Ischemia, Injury & Infarction (ST changes, exercise-induced) 4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

5 Pharmacology for the Clinical Exercise Physiologist

5.1 Beta-Blockers, Calcium-Channel Blockers & Nitrates 5.2 RAAS Agents, Diuretics, Antiarrhythmics, Lipid-Lowering & Antithrombotic Drugs 5.3 Bronchodilators, Corticosteroids, Insulin & Oral Antidiabetic Agents 5.4 Medication Effects on HR/BP & Exercise Response; Dose/Meal/Dialysis Timing

6 Patient Assessment (Domain I, 18%)

6.1 Medical Records, HIPAA/HITRUST, Charting & Physician Referral 6.2 Patient Interview, Medical History & Medication Reconciliation 6.3 Resting Vital Signs, Body Composition & Resting ECG 6.4 Preparticipation Health Screening & Level of Monitoring (PAR-Q+, ACSM algorithm, ACC/AHA · GOLD · ADA · AACVPR) 6.5 Assessing Patient Goals, Readiness & Psychosocial Status

7 Clinical Exercise Testing (Domain II, 18%)

Submaximal Aerobic Tests (treadmill, cycle, step, 6-minute walk) Musculoskeletal Fitness, Mobility & Balance Testing Maximal Symptom-Limited GXT: Protocols, Contraindications & ECG Prep Test Termination: Relative & Absolute Indications Interpreting & Reporting Results (ECG response, RPP, claudication, Duke Treadmill Score, VO₂/RER/AT)

8 Exercise Prescription for Clinical Populations (Domain III, 22%)

FITT-VP Principles, Progression & Prescription Foundations Ex Rx for Cardiovascular Disease (CAD, HF, HTN, PAD, post-revascularization) Ex Rx for Pulmonary Disease (COPD, asthma; breathing techniques, supplemental O2) Ex Rx for Diabetes, Metabolic Syndrome & Obesity Ex Rx for Musculoskeletal, Neuromuscular, Neoplastic & Other Conditions Communicating Intensity (THR, RPE, talk test), Monitoring & Modifying the Prescription

9 Exercise Training & Leadership (Domain IV, 24%)

9.1 Discussing the Training Plan, Clinician & Patient Expectations/Goals 9.2 Instructing & Modifying Exercise Modes (cardiorespiratory, strength/endurance, flexibility, coordination, agility) 9.3 Patient Monitoring & Supervision During Exercise (telemetry, oximetry, glucometry, ECG) 9.4 Contraindications to Training & Modifying Recommendations 9.5 Documenting Clinical Status, Reporting Adverse Events & Interdisciplinary Coordination

10 Education & Behavior Change (Domain V, 13%)

10.1 Behavioral-Health Screening & Recognizing Distress (PHQ-9, Beck, SF-36; referral) 10.2 Patient Education, Health Literacy & Disease Self-Management 10.3 Motivational Interviewing & Behavior-Change Theories (Transtheoretical, HBM, Social Cognitive, Five-A's) 10.4 Promoting Adherence, Self-Efficacy, Relapse Prevention & Social Support

11 Legal, Professional & Emergency Management (Domain VI, 5%)

11.1 Emergency Equipment, Crash Cart Inspection & Emergency Procedures 11.2 CPR/AED/BLS/ACLS, Universal Precautions & EMS Activation 11.3 Scope of Practice, Legal/Ethical Standards, Liability/Negligence, Informed Consent & Professional Organizations (ACSM/AACVPR/AHA)

4.4 Drug & Electrolyte ECG Effects; Resting/Exercise Monitoring Setup & Lead Placement

Key Takeaways Explain This Topic AI

Digoxin produces a characteristic downsloping, "scooped" ST segment and can shorten the QT interval, even at therapeutic doses

Hyperkalemia classically produces tall, peaked (tented) T waves and, as it worsens, a widened QRS and flattened P wave

Hypokalemia produces flattened or inverted T waves, prominent U waves, ST depression, and a prolonged QT interval

Standard precordial lead placement runs from V1 (4th intercostal space, right sternal border) to V6 (midaxillary line, same level as V4-V5)

The Mason-Likar modification moves limb electrodes onto the torso to reduce motion artifact during exercise ECG monitoring

Last updated: July 2026

Drug & Electrolyte ECG Effects; Monitoring Setup & Lead Placement

Quick Answer: Digoxin causes a characteristic scooped ST depression and can shorten the QT interval. Hyperkalemia progresses from tall, peaked T waves to a widened QRS and flattened P wave as potassium rises, while hypokalemia causes flattened T waves, prominent U waves, and a prolonged QT interval. Correct electrode placement follows a standard 12-lead map, but exercise testing uses the Mason-Likar modification, which relocates limb electrodes to the torso to minimize motion artifact.

Medications and electrolyte disturbances can alter the resting ECG in recognizable, testable patterns. A clinical exercise physiologist must also apply electrodes correctly, since misplacement is a common and preventable source of ECG misinterpretation.

Digoxin Effects

Digoxin (used for heart failure and atrial fibrillation rate control) produces changes even at therapeutic doses that must not be confused with ischemia:

"Digoxin effect": A gradual, downsloping, scooped ST-segment depression (sometimes described as a sagging or "reverse checkmark" appearance), most visible in leads with tall R waves

Shortened QT interval
Flattened or inverted T waves

At toxic levels, digoxin becomes markedly proarrhythmic and can precipitate a wide range of arrhythmias, including PVCs, atrial tachycardia with block, and high-grade AV block — any new arrhythmia in a patient on digoxin should raise concern for toxicity, particularly if renal function is impaired or potassium is low.

Hyperkalemia

As serum potassium rises, ECG changes progress in a predictable sequence:

Mild elevation: Tall, narrow, peaked ("tented") T waves — often the earliest and most recognizable sign
Moderate elevation: Flattened or absent P waves, prolonged PR interval

Severe elevation: Widened QRS complex , and in extreme cases the QRS and T wave merge into a sine-wave pattern that precedes ventricular fibrillation or asystole

Hyperkalemia is a medical emergency once ECG changes appear, and any patient with these findings should not be exercise tested until it is corrected.

Hypokalemia

Low serum potassium produces largely opposite changes:

Flattened or inverted T waves
Prominent U waves (a small deflection following the T wave)
ST-segment depression

Prolonged QT interval — which raises the risk of dangerous ventricular arrhythmias, including torsades de pointes

Calcium Abnormalities

Calcium primarily affects the QT interval rather than the T wave: hypercalcemia shortens the QT interval , while hypocalcemia prolongs the QT interval . A prolonged QT from any cause — hypocalcemia, hypokalemia, or certain medications — increases the risk of torsades de pointes and should prompt caution before beginning an exercise test.

Standard 12-Lead Electrode Placement

Accurate interpretation depends on correct electrode placement. The six precordial (chest) leads are placed as follows:

Lead Location
V1 4th intercostal space, right sternal border
V2 4th intercostal space, left sternal border
V3 Midway between V2 and V4
V4 5th intercostal space, midclavicular line
V5 Anterior axillary line, same horizontal level as V4
V6 Midaxillary line, same horizontal level as V4-V5

The four limb electrodes (RA, LA, RL, LL) are placed on their respective limbs for a standard resting 12-lead, with RL serving as the ground/reference electrode. A common technical error is arm-lead reversal (swapping RA and LA), which produces a negative P wave and QRS in lead I along with an abnormal-appearing rightward axis that can mimic pathology in an otherwise healthy patient. Whenever an unexpected axis or morphology change appears, checking electrode placement should be the first troubleshooting step before assuming a new cardiac abnormality. Proper skin preparation — clipping hair, mild abrasion, and cleaning with alcohol — along with firm electrode contact also reduces baseline wander and artifact that can otherwise be mistaken for atrial fibrillation or other rhythm disturbances.

The Mason-Likar Modification for Exercise Testing

Limb electrodes placed on the arms and legs generate excessive motion artifact once a patient starts walking or cycling. The Mason-Likar modification , used for virtually all clinical exercise ECG monitoring, relocates the limb electrodes onto the torso:

RA and LA electrodes move to the infraclavicular fossae (just below the clavicles, near the shoulders)
RL and LL electrodes move to the torso near the iliac crest, below the rib cage

The six precordial (V1-V6) electrode positions stay the same as standard placement. Because moving the limb electrodes onto the torso changes the electrical vector slightly, the Mason-Likar tracing is not perfectly identical to a true resting 12-lead — clinicians should be aware that it can subtly alter axis and amplitude, though it remains the accepted standard for exercise testing because motion artifact reduction outweighs this small tradeoff.